Twelve weeks of resistance band exercise training improves age-associated hormonal decline, blood pressure, and body composition in postmenopausal women with stage 1 hypertension: a randomized clinical trial

Abstract

Objective: Menopause is often accompanied by an age-associated hormonal decline, increased blood pressure (BP), and poor body composition, which may collectively increase risks for cardiovascular disease. It is important to combat the negative effects on age-associated hormonal decline, BP, and body composition by incorporating appropriate lifestyle interventions, such as exercise. We sought to examine the effects of a 12-week resistance band exercise training program on aging-related hormones including estradiol, growth hormone (GH), insulin-like growth factor-1 (IGF-1), and dehydroepiandrosterone sulfate (DHEA-S), BP, and body composition in postmenopausal women with stage 1 hypertension.

Methods: Postmenopausal women with stage 1 hypertension (n = 20) were recruited and randomly assigned to a 12-week resistance band exercise training group (EX, n = 10) or control group (CON, n = 10). The EX group performed a total-body resistance band exercise training program. Levels of estradiol, GH, IGF-1, DHEA-S, as well as BP and body composition were assessed before and after 12 weeks.

Results: There were significant group by time interactions (P < 0.05) for estradiol, GH, IGF-1, DHEA-S, and lean body mass, which significantly increased (P < 0.05), and systolic BP, total body mass, body mass index, and body fat percentage, which significantly decreased (P < 0.05) after EX compared to no changes in CON. There were no significant differences (P > 0.05) in diastolic BP after 12 weeks.

Conclusions: These results indicate that 12 weeks of resistance band exercise may be an effective, easily accessible, and cost-efficient intervention for improving age-associated hormonal decline, high BP, and poor body composition in postmenopausal women with stage 1 hypertension. : Video Summary: http://links.lww.com/MENO/A494.

Trial registration: ClinicalTrials.gov NCT03919201.